What Standard Bloodwork Misses About Hidden Inflammation

Standard blood panels are designed to detect acute illness, not the slow-burning, low-grade inflammation that drives biological aging and chronic disease. Understanding the difference between these two inflammatory states — and knowing which biomarkers actually measure each — is the foundation of any serious preventive health strategy.

For a broader understanding of how chronic inflammation connects to biological age, see our guide Chronic Inflammation & Inflammaging: The Hidden Driver of How You Age.

What is the difference between acute inflammation and chronic inflammation?

Acute inflammation is the body's immediate defense response to injury, infection, or tissue damage. It is protective, time-limited, and measurable through conventional blood markers. Chronic inflammation is a fundamentally different process: the persistent, low-grade over-activation of the immune system that accumulates quietly over years, creating a biological environment associated with cardiovascular disease, metabolic dysfunction, neurological decline, and autoimmune conditions. Where acute inflammation resolves once the threat is cleared, chronic inflammation does not. It becomes a background condition that standard bloodwork was never designed to detect.

What is inflammaging, and why does it matter for long-term health?

Inflammaging is the gradual, age-related increase in systemic chronic inflammation that accelerates biological aging and underlies most major chronic diseases. It is not a single event but a sustained shift in immune function, as the immune system becomes progressively dysregulated, producing more pro-inflammatory signals and fewer anti-inflammatory ones as we age. Research shows that elevated inflammatory markers predict higher mortality risk, and inflammaging is a leading contributor to three out of five deaths worldwide. The challenge is that inflammaging operates below the threshold that standard clinical tests are calibrated to detect, which means it is often invisible until disease has already taken hold.

Why do 3 out of 5 deaths involve chronic inflammatory disease?

Chronic inflammation is the common biological mechanism linking the most prevalent causes of death, including cardiovascular disease, type 2 diabetes, neurodegeneration, and certain cancers. It does not cause these diseases in isolation; rather, it creates and sustains the conditions in which they develop. In cardiovascular disease, for example, chronic inflammation initiates and drives the progression of atherosclerosis: damaged blood vessels trigger an inflammatory response, macrophages accumulate oxidized LDL cholesterol to form foam cells, those foam cells secrete further inflammatory molecules, and the resulting arterial plaque can rupture to cause heart attack or stroke.

"As we get older, inflammation starts to become our enemy — from our defender, it becomes our enemy. Inflammation is underlying so many different chronic diseases of middle and old age. The low-grade chronic inflammation that happens all around the body, all the time, is consuming a huge amount of energy and at the same time leaving microscopic scars of damage — which then promotes more inflammation. It is a vicious circle that leads to aging."

— Prof. Gordan Lauc, Co-Founder & Chief Scientific Officer, GlycanAge

The same inflammatory biology appears across metabolic disease, neurological conditions, and autoimmune disorders. Measuring and managing chronic inflammation is therefore not a niche concern, but the central task of preventive medicine.

What does a standard blood panel actually test for?

A standard blood panel, including CRP, ESR, ferritin, white blood cell count, and fibrinogen, measures markers of the acute inflammatory response, not chronic systemic inflammation. These markers are designed to detect active infection, tissue injury, or acute illness, and they perform that function well. The problem is that they fluctuate rapidly with short-term biological events and are non-specific: elevated CRP, for instance, can reflect infection, injury, obesity, autoimmune activity, or advanced age, making it difficult to isolate a chronic inflammatory signal. As a clinical resource, standard bloodwork answers the question "is something acutely wrong right now?", but it does not answer "how fast is this person's immune system aging?"

Why can't high-sensitivity CRP reliably measure chronic inflammation?

High-sensitivity CRP (hs-CRP) is a more sensitive version of the standard CRP test, but it remains a marker of acute-phase inflammatory activity rather than chronic low-grade inflammation. Its concentration changes in response to the same acute triggers, such as infection, injury, smoking, obesity, that confound standard CRP, and it cannot distinguish between these sources. Clinicians using hs-CRP to assess chronic inflammation must first rule out all acute confounders, which limits its practical utility as a standalone chronic inflammation biomarker. More critically, hs-CRP tends to change close to the point of established disease, and by the time it signals a problem, the biological damage has often already accumulated over years.

What about ESR, ferritin, and white blood cell count — are these useful for chronic inflammation?

Erythrocyte sedimentation rate (ESR) is an indirect, non-specific measure of inflammation that rises 24 to 48 hours after an inflammatory process begins. It is confounded by advanced age, female sex, anemia, autoimmunity, and obesity, meaning any elevation requires extensive differential diagnosis before it can be attributed to chronic inflammation. Ferritin is primarily a marker of iron status; while high levels can indicate inflammation, they also indicate iron overload or liver disease, and low levels indicate iron deficiency, making it a poor candidate for chronic inflammation monitoring. White blood cell count with a differential can indicate where in the inflammatory process a patient sits, but it is not routinely used to assess chronic systemic inflammation. Platelet count is recognized as a factor in the acute inflammatory response and may have some utility in tracking inflammation, but the research base for this application remains limited.

What are the newer inflammation biomarkers, and do they solve the problem?

Newer biomarkers such as suPAR show prognostic value in acute clinical settings, but their response time, cross-disease elevation, and lack of standardisation across analytical methods limit their utility for tracking chronic low-grade inflammation or monitoring intervention response. SuPAR is elevated across a wide range of conditions, from infections to cancers, and takes several weeks to reflect any change, which makes it poorly suited to the kind of longitudinal, intervention-tracking work that preventive medicine requires.

What are glycans, and why are they a better measure of chronic inflammation?

Glycans are complex sugar molecules attached to the surface of virtually every cell and the majority of proteins in the human body. They are not passive structural components, instead they function as a biological communication system, enabling cells and proteins to signal to one another and regulating core immune processes. When the immune system becomes dysregulated through aging, disease, or lifestyle factors, the composition of these glycans changes in predictable, measurable ways. Specifically, the balance shifts toward pro-inflammatory glycan structures and away from anti-inflammatory ones and it reflects the underlying state of chronic inflammation with a precision that acute-phase markers cannot match.

How does IgG glycosylation reflect biological age and chronic inflammation?

Immunoglobulin G (IgG) is the most abundant antibody in human blood and a central player in adaptive immune function. IgG molecules carry multiple glycans (complex sugars) that fine-tune how the antibody behaves: certain glycan structures activate inflammatory pathways (pro-inflammatory), while others suppress them (anti-inflammatory). The overall profile of IgG glycans in a person, called the IgG glycome, reflects the level of chronic inflammation in their body. As people age, the IgG glycome undergoes striking, consistent changes: pro-inflammatory glycan structures become more frequent, and anti-inflammatory structures decline. This predictable pattern enabled the development of the glycan clock, the first biological age biomarker based solely on glycan analysis.

How does GlycanAge measure chronic inflammation differently from standard blood tests?

GlycanAge measures 29 different glycan structures attached to IgG antibodies from a simple blood sample, calculating the ratio of pro-inflammatory to anti-inflammatory glycans to determine a person's biological age. Unlike acute-phase markers such as CRP or ESR, which respond to short-term events and fluctuate daily, IgG glycans reflect the cumulative, chronic inflammatory state of the immune system. They change in response to the sustained biological processes that drive aging, not to transient illness or injury. Critically, glycans respond to lifestyle and pharmacological interventions, such as diet, exercise, weight loss, hormone optimization, and supplementation, making them actionable as a monitoring tool, not just a snapshot. GlycanAge is not a diagnostic tool; it is a validated biomarker of immune aging and chronic inflammation, designed to be interpreted alongside clinical history and other health data.

Why do standard blood tests miss chronic inflammation until disease is already present?

Standard inflammatory markers are calibrated to detect acute biological events — the kind of inflammation that is loud, fast, and clinically obvious.

"The problem with modern medicine is that it is based on a relatively old way of categorising diseases — by looking at symptoms and location. But the molecular events are overlapping in many of these diseases. What modern science is trying to understand is what the underlying molecular mechanisms are, and we know glycans are important there."

— Prof. Gordan Lauc, Chief Scientific Officer, GlycanAge

Chronic low-grade inflammation operates at a different biological register: it is persistent rather than episodic, systemic rather than localized, and it accumulates over years before producing the tissue damage that conventional tests can detect. By the time CRP, ESR, or white blood cell count signal a problem, the inflammatory biology has typically been driving cellular damage for a decade or more. What preventive medicine requires is a marker that changes before disease takes hold and captures the chronic inflammatory trajectory while there is still time to alter it.

Who should consider testing for chronic inflammation beyond standard bloodwork?

If you are making deliberate lifestyle or medical changes and want to know whether they are working at a biological level, you need a biomarker that measures the biology those interventions are designed to change. The following groups have the most direct interest in testing beyond standard blood panels:

People with a family history of cardiovascular disease, metabolic syndrome, autoimmune conditions, or neurodegeneration benefit from measuring chronic inflammation before symptoms appear. Perimenopausal and menopausal women experience accelerated shifts in immune function and inflammatory biology that standard panels do not capture. Executives and high-performers under sustained occupational stress, athletes managing training load and recovery, and individuals managing weight or metabolic health all operate in biological contexts where chronic inflammation is likely elevated but clinically invisible.

For functional medicine practitioners and longevity clinicians, chronic inflammation testing provides an objective, longitudinal signal that standard bloodwork cannot: how fast is this patient's immune system aging, and is our intervention changing that trajectory?

How often should chronic inflammation be tested, and when do results become meaningful?

The appropriate testing cadence depends on what you are trying to measure. For baselining, meaning establishing where someone's inflammatory biology sits before any intervention, a single test provides the reference point. For tracking intervention effectiveness, retesting after three to six months captures the window in which meaningful biological change becomes detectable through glycan analysis. Standard acute-phase markers are not suitable for this purpose: their daily fluctuation means a change in result may reflect last week's illness rather than a genuine shift in chronic inflammatory status. A biomarker used for intervention tracking needs to be stable in the absence of biological change and responsive when real change occurs. These two properties distinguish glycan-based measurement from conventional blood chemistry.

Can chronic inflammation be reduced, and how would you know if an intervention is working?

Chronic inflammation is modifiable. Daily choices, such as diet, exercise, sleep quality, stress management, influence the levels of chronic inflammation and shape the trajectory of biological aging. Pharmacological interventions, including hormone therapy, also produce measurable changes in inflammatory biology. The challenge has always been verification: how do you know whether a given intervention is actually working at the level of immune biology, rather than simply improving subjective wellbeing or shifting a non-specific marker? A biomarker that responds to interventions in a clinically meaningful timeframe, and that is stable enough to distinguish real biological change from measurement noise, is the answer to that question.

"There is no single biomarker that can function for everything, but glycans are predictive, they are responsive, they are stable. They are such a great indicator of inflammation and a very good biomarker of aging."

— Raffaele Medical, New York City (GlycanAge clinical partner)

Glycan analysis published across interventional studies covering diet, weight loss, exercise, supplementation, and hormone optimization demonstrates that IgG glycans respond to all of these, providing an objective signal that an intervention is producing genuine biological change.

How should a functional medicine practitioner integrate chronic inflammation testing into their clinical workflow?

The most practical integration point is baselining: test before initiating any significant intervention, whether that is a dietary protocol, a supplement regimen, hormone therapy, or a structured exercise program, so that subsequent retesting can demonstrate objective biological change to the patient. Chronic inflammation testing sits alongside, not instead of, standard blood panels. Where a CBC, metabolic panel, or lipid profile answers questions about acute health status and organ function, a glycan-based biological age test answers the question standard panels cannot: how fast is this patient's immune system aging, and is our intervention changing that trajectory? For practitioners running preventive or longevity-focused practices, this combination of standard bloodwork plus a validated chronic inflammation biomarker is what turns a health check into a longitudinal monitoring strategy.

If you are ready to measure your chronic inflammation with a validated biomarker — not a proxy for acute illness — the GlycanAge at-home test gives you a biological age grounded in 30 years of glycoscience research and over 350 published papers. Every test includes a 1:1 Result Interpretation Call with a longevity specialist who will walk you through your results and help you build a targeted plan.

Order your GlycanAge test → Shop the GlycanAge Test Kit

For functional medicine practitioners and longevity clinicians looking to integrate chronic inflammation monitoring into patient care, our Healthcare Providers page outlines how GlycanAge fits into clinical workflows, supports intervention validation, and drives patient retention through repeat testing.

Integrate GlycanAge into your practice → Healthcare Providers

External Sources

• https://www.nature.com/articles/s41591-019-0675-0 — Furman D, et al. Chronic inflammation in the etiology of disease across the life span. Nature Medicine. 2019;25(12):1822–1832.

• https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0082558 — Menni C, Keser T, Lauc G, et al. Glycosylation of immunoglobulin G: role of genetic and epigenetic influences. PLOS One. 2013;8(12):e82558.

• https://www.ahajournals.org/doi/10.1161/hc0902.104353 — Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–1143.

• https://pubmed.ncbi.nlm.nih.gov/12588750/ — Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107(3):363–369.